Research Article
Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
Table 2
Evaluation of hemoglobin, and erythrocyte indices of the CRC patients, during six cycles of adjuvant/palliative chemotherapy, without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values expressed as mean (SD). Hb: hemoglobin, MCH: mean corpuscular hemoglobin, MCV: mean corpuscular volume. UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300 mg/day (), C group: patients treated with FOLFOX4 (); *; **; *** in relation to the day 0. |